Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity
Amblyomin-X, a Kunitz-type protease inhibitor, is a recombinant protein that selectively induces apoptosis in tumor cells and promotes tumor reduction in vivo in melanoma animal models. Furthermore, Amblyomin-X was able to drastically reduce lung metastasis in a mice orthotopic kidney tumor model. D...
Main Authors: | Durvanei A. Maria, Sonia Elisabete A.L. Will, Rosemary V. Bosch, Jean G. Souza, Juliana M. Sciani, Mauricio B. Goldfeder, Giuliana G. Rondon, Ana M. Chudzinski-Tavassi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Toxicology Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214750018305468 |
Similar Items
-
Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X.
by: Mario T F Pacheco, et al.
Published: (2014-01-01) -
Structural and functional properties of the Kunitz-type and C-terminal domains of Amblyomin-X supporting its antitumor activity
by: K. L. P. Morais, et al.
Published: (2023-02-01) -
Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells
by: Mariana Costa Braga Schmidt, et al.
Published: (2020-01-01) -
A Kunitz-type inhibitor from tick salivary glands: A promising novel antitumor drug candidate
by: Aline R. M. Lobba, et al.
Published: (2022-08-01) -
Plant Kunitz Inhibitors and Their Interaction with Proteases: Current and Potential Pharmacological Targets
by: Camila Ramalho Bonturi, et al.
Published: (2022-04-01)